{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "10619594",
  "DateCompleted": {
    "Year": "2000",
    "Month": "01",
    "Day": "20"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "05",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0895-7061",
      "JournalIssue": {
        "Volume": "12",
        "Issue": "12 Pt 1-2",
        "PubDate": {
          "Year": "1999",
          "Month": "Dec"
        }
      },
      "Title": "American journal of hypertension",
      "ISOAbbreviation": "Am J Hypertens"
    },
    "ArticleTitle": "From hypertension to heart disease: interfering with progression.",
    "Pagination": {
      "StartPage": "149S",
      "MedlinePgn": "149S"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Neutel",
        "ForeName": "J M",
        "Initials": "JM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Am J Hypertens",
    "NlmUniqueID": "8803676",
    "ISSNLinking": "0895-7061"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Adrenergic beta-Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensin Receptor Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antihypertensive Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptor, Angiotensin, Type 1"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Receptor, Angiotensin, Type 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Adrenergic beta-Antagonists"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Angiotensin Receptor Antagonists"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antihypertensive Agents"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Blood Pressure"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Progression"
    },
    {
      "QualifierName": [
        "epidemiology",
        "etiology",
        "prevention & control"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Hypertension"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Incidence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Receptor, Angiotensin, Type 1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Receptor, Angiotensin, Type 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Survival Rate"
    }
  ]
}